Revolutionizing precision medicine: OncoDNA’s data innovation story

Once upon a time, in a world where personalized medicine was a luxury reserved for the few, a small but passionate group embarked on an audacious journey to change precision medicine. It was a crazy idea, fueled by a burning desire to make a difference. Ten years ago, this determined team set out to create a company that would revolutionize healthcare and bring personalized medicine within reach of all.

The team was an eclectic mix of individuals, each with their own unique talents and quirks. One faction of the group dedicated themselves to pushing the boundaries of physical tests, tirelessly innovating and developing a groundbreaking technology called OncoDEEP®. This technology would enable deep insights into individual patients’ conditions, paving the way for tailored treatments.

Meanwhile, the rest of the team consisted of three brilliant geeks who immersed themselves in the world of data. They were convinced that knowledge, not just vast amounts of data, would be the key to survival in the industry. Driven by this conviction, they poured their hearts and minds into building the future of data analytics. They understood that true success lay in the marriage of deep, high-quality data and human insight.

The path they chose was far from easy. They encountered numerous challenges along their journey : limited resources and a relentless pressure to explore different areas, regulations, competitors’ data. They had to deal with rules and the constant threat of other companies having their information, which always tested their determination. However, despite all these difficulties, the team did not let anything stop them from achieving their goal.

Their secret weapon was their agility and speed compared to their competitors. They embraced a philosophy of constant innovation and invested heavily in researching new solutions. This dedication paid off: they soon witnessed remarkable success with their physical tests, especially in the field of liquid biopsy. This innovative technology posed a challenge to major providers.

Over the years,  they assiduously built a comprehensive database called OncoKDO®. This invaluable resource housed a treasure trove of oncology-related information, including NGS data, clinical trials, and much more. While algorithms played their part in populating the database, the team insisted on human curation to ensure its quality. They firmly believed that AI could never replace the expertise and intuition of a human mind.

Armed with their deep knowledge in the field, partially owed to their heterogenous and high-quality data,  they ventured into creating innovative products. The OncoDEEP Kit became a beacon of hope for patients, enabling personalized treatment plans based on individual profiles. Simultaneously, their data-driven solutions, such as the enigmatic Onco****, brought a blend of business intelligence and AI tools for efficient data analysis.

Throughout their journey, learning became the cornerstone of their success. They embraced a design thinking approach, allowing them to iterate swiftly and adapt to the ever-changing landscape. Their strategy of prioritizing data quality and architecture, though requiring patience, ultimately proved to be the key that unlocked their success.
In the world of data, their story is an important lesson. They remind us to always keep learning, to constantly look for new ideas and ways to improve. They encourage us to approach problems with a creative mindset, which helps us deal with the challenges of today’s world. Most importantly, they teach us how crucial it is to focus on having good data and a solid structure. This strong foundation will lead to the best outcomes in the long run.

And so, their legacy lives on—a testament to the power of a small, crazy group that dared to dream and reshaped the future of personalized medicine for all.

Gregori Ghitti – Chief Data Innovation Officer

Stay connected !

"We are working on an advanced BI/AI application (name will be revealed soon) which will unlock lab knowledge by seamlessly integrating dimensions, enabling effortless data exploration, and utilizing deep learning algorithms to provide comprehensive insights."
oncodna-gregori ghitti
Gregori Ghitti
CDIO

You may also be interested in these resources

Press Release

OncoDNA laboratory has received the CAP accreditation

Gosselies, January 4th – The Certificate of Accreditation has been issued to the IntegraGen laboratory by The College of American Pathologists (CAP) for having successfully met the Laboratory Accreditation Program Standards. “The CAP accreditation is a critical step for OncoDNA, and we...

Scientific Application Note

MELANOMA: In a retrospective study of patients with advanced disease who achieved a complete response to immunotherapy, cessation of therapy was associated with a 27% risk of subsequent disease progression.

LONG-TERM OUTCOMES AND RESPONSES TO RETREATMENT IN PATIENTS WITH MELANOMA TREATED WITH PD-1 BLOCKADE Allison Betof Warner, et JP Journal Of Clinical Oncology Volume 38, Issue 15 PURPOSE To analyze long-term outcomes after treatment discontinuation of anti–programmed...

Share This